Lupin included in S&P Global Sustainability Yearbook 2025 for the second consecutive year
Lupin’s S&P Global CSA score has significantly improved from 65 to 75 in 2024
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Lupin receives US FDA Establishment Inspection Report for Somerset facility
The inspection, conducted in January 2025, confirms compliance standards at Lupin’s New Jersey manufacturing site
Lupin receives “A-” leadership rating from CDP for climate change and water security
Lupin improves its CDP scores, reflecting progress in sustainability efforts, carbon footprint reduction, and water management
Lupin receives U.S. FDA approval for generic Ipratropium Bromide nasal spray
Approval allows marketing of generic equivalent of Atrovent Nasal Spray in the U.S.
Lupin receives tentative FDA approval for generic Darunavir combination tablets
It will be manufactured at Lupin’s Nagpur facility in India
Lupin’s Somerset facility clears U.S. FDA Pre-Approval Inspection for Edaravone Oral Suspension
Lupin announces completion of U.S. FDA Pre-Approval Inspection at its Somerset, New Jersey facility with zero 483 observations
Lupin and Avas launch NaMuscla in Italy
Avas will initially commercialise NaMuscla as a Class C (Tier 2), while Lupin negotiates with AIFA (Agenzia Italiana del Farmaco)…
Lupin gains USFDA approval for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension
The fixed-dose combination is indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and…
Lupin launches Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate…
Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets (RLD Balcoltra) had an estimated annual sale of…
Trends 2025: Redefining the pharma supply chain
Saurabh Gupta, Global Head of Supply Chain, Lupin highlights trends such as AI integration, digitalisation and sustainability that…